Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Yingyi Long"'
Autor:
Tingting Li, Xiaojian Han, Chenjian Gu, Hangtian Guo, Huajun Zhang, Yingming Wang, Chao Hu, Kai Wang, Fengjiang Liu, Feiyang Luo, Yanan Zhang, Jie Hu, Wang Wang, Shenglong Li, Yanan Hao, Meiying Shen, Jingjing Huang, Yingyi Long, Shuyi Song, Ruixin Wu, Song Mu, Qian Chen, Fengxia Gao, Jianwei Wang, Shunhua Long, Luo Li, Yang Wu, Yan Gao, Wei Xu, Xia Cai, Di Qu, Zherui Zhang, Hongqing Zhang, Na Li, Qingzhu Gao, Guiji Zhang, Changlong He, Wei Wang, Xiaoyun Ji, Ni Tang, Zhenghong Yuan, Youhua Xie, Haitao Yang, Bo Zhang, Ailong Huang, Aishun Jin
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Neutralizing antibodies are currently one versatile strategy to treat SARS-CoV-2 infection. Here, Li et al. characterize three monoclonal antibodies neutralizing authentic virus infection in vitro and in vivo by targeting the receptor binding domain
Externí odkaz:
https://doaj.org/article/7abf996e0f9d4da6b7b08529e0aeb206
Autor:
Xiaojian Han, Yingming Wang, Shenglong Li, Chao Hu, Tingting Li, Chenjian Gu, Kai Wang, Meiying Shen, Jianwei Wang, Jie Hu, Ruixin Wu, Song Mu, Fang Gong, Qian Chen, Fengxia Gao, Jingjing Huang, Yingyi Long, Feiyang Luo, Shuyi Song, Shunhua Long, Yanan Hao, Luo Li, Yang Wu, Wei Xu, Xia Cai, Qingzhu Gao, Guiji Zhang, Changlong He, Kun Deng, Li Du, Yaru Nai, Wang Wang, Youhua Xie, Di Qu, Ailong Huang, Ni Tang, Aishun Jin
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
After the pandemic of COVID-19, neutralizing antibodies (NAbs) against SARS-CoV-2 have been developed for the prophylactic and therapeutic purposes. However, few methodologies are described in detail on how to rapidly and efficiently generate effecti
Externí odkaz:
https://doaj.org/article/2d7d25b67cdc43baad622b60c8f638e5
Autor:
Yingyi Long, Wang Wang, Aishun Jin, Chao Hu, Shuyi Song, Huajun Zhang, Xiaojian Han, Shenglong Li, Bo Zhang, Feiyang Luo, Yingming Wang, Tingting Li
Publikováno v:
Biochemical and Biophysical Research Communications
Potent neutralizing antibodies (Abs) have been proven with therapeutic efficacy for the intervention against SARS-CoV-2. Majority of these Abs function by directly interfering with the virus entry to host cells. Here, we identified a receptor binding
Autor:
Kai Wang, Xiaojian Han, Zhe-Rui Zhang, Ailong Huang, Shuyi Song, Jie Hu, Guiji Zhang, Yan Gao, Chenjian Gu, Hong-Qing Zhang, Aishun Jin, Changlong He, Bo Zhang, Ruixin Wu, Chao Hu, Luo Li, Qian Chen, Shenglong Li, Ya-Nan Zhang, Shunhua Long, Wang Wang, Fengxia Gao, Jingjing Huang, Tingting Li, Xia Cai, Wei Xu, Na Li, Song Mu, Meiying Shen, Feiyang Luo, Wang Wei, Yanan Hao, Ni Tang, Yang Wu, Haitao Yang, Jianwei Wang, Youhua Xie, Huajun Zhang, Zhenghong Yuan, Di Qu, Fengjiang Liu, Yingming Wang, Yingyi Long, Qingzhu Gao, Hangtian Guo, Xiaoyun Ji
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Nature Communications
Nature Communications
Accumulating mutations in the SARS-CoV-2 Spike (S) protein can increase the possibility of immune escape, challenging the present COVID-19 prophylaxis and clinical interventions. Here, 3 receptor binding domain (RBD) specific monoclonal antibodies (m
Autor:
Guiji Zhang, Yan Gao, Shunhua Long, Hong-Qing Zhang, Qian Chen, Wang Wei, Luo Li, Ruixin Wu, Fangjiang Liu, Chao Hu, Wang Wang, Huajun Zhang, Zhenghong Yuan, Yingyi Long, Ailong Huang, Youhua Xie, Xia Cai, Ni Tang, Di Qu, Haitao Yang, Xiaojian Han, Chenjian Gu, Xiaoyun Ji, Jie Hu, Kai Wang, Shuyi Song, Changlong He, Meiying Shen, Na Li, Yanan Hao, Shenglong Li, Qingzhu Gao, Yingming Wang, Hangtian Guo, Ya-Nan Zhang, Wei Xu, Tingting Li, Jingjing Huang, Bo Zhang, Feiyang Luo, Jianwei Wang, Yang Wu, Song Mu, Zhe-Rui Zhang, Aishun Jin, Fengxia Gao
Accumulating mutations in the SARS-CoV-2 Spike (S) protein can increase the possibility of immune escape, challenging the present COVID-19 prophylaxis and clinical interventions. Here, 3 receptor binding domain (RBD) specific monoclonal antibodies (m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e874d892ab2e7988ea3947012a620e8
https://doi.org/10.1101/2021.04.19.440481
https://doi.org/10.1101/2021.04.19.440481
Autor:
Ni Tang, Jingjing Huang, Guiji Zhang, Chao Hu, Feiyang Luo, Shunhua Long, Li Du, Youhua Xie, Ailong Huang, Aishun Jin, Tingting Li, Changlong He, Ruixin Wu, Xia Cai, Chenjian Gu, Fengxia Gao, Xiaojian Han, Jie Hu, Shenglong Li, Wei Xu, Qian Chen, Luo Li, Yingyi Long, Jianwei Wang, Shuyi Song, Yaru Nai, Kun Deng, Di Qu, Fang Gong, Yingming Wang, Zhenghong Yuan, Qingzhu Gao, Yang Wu, Song Mu, Meiying Shen, Kai Wang, Wang Wang, Yanan Hao
The spread of SARS-CoV-2 confers a serious threat to the public health without effective intervention strategies1–3. Its variant carrying mutated Spike (S) protein D614G (SD614G) has become the most prevalent form in the current global pandemic4,5.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c0db2b3f785ea5761d40850427abf59
https://doi.org/10.1101/2020.09.11.292631
https://doi.org/10.1101/2020.09.11.292631
Autor:
Song Mu, Shuyi Song, Wang Wang, Kun Deng, Jianwei Wang, Yang Wu, Aishun Jin, Jingjing Huang, Fang Gong, Feiyang Luo, Yaru Nai, Fengxia Gao, Chenjian Gu, Jie Hu, Yingming Wang, Meiying Shen, Ni Tang, Ruixin Wu, Qian Chen, Yanan Hao, Youhua Xie, Ailong Huang, Luo Li, Qingzhu Gao, Li Du, Yingyi Long, Shunhua Long, Guiji Zhang, Di Qu, Wei Xu, Kai Wang, Chao Hu, Xia Cai, Xiaojian Han, Tingting Li, Changlong He, Shenglong Li
Neutralizing antibodies (Abs) have been considered as promising therapeutics for the prevention and treatment of pathogens. After the outbreak of COVID-19, potent neutralizing Abs to SARS-CoV-2 were promptly developed, and a few of those neutralizing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13af01ad2f1c928c0681537e57caf85e
https://doi.org/10.1101/2020.08.19.253369
https://doi.org/10.1101/2020.08.19.253369